Document Detail


Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.
MedLine Citation:
PMID:  23614996     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The possible impact of coinfection with the Kaposi sarcoma-associated herpes virus (KSHV) on the response to antiretroviral therapy (ART) is unknown. Prospective studies are rare, particularly in Africa.
METHODS: We enrolled a prospective cohort of HIV-infected adults initiating ART in Johannesburg, South Africa. The subjects were defined as seropositive to KSHV if they were reactive to either KSHV lytic K8.1 or latent Orf73 antigen or to both. The subjects were followed from ART initiation until 18 months of treatment. HIV viral load and CD4 counts were tested 6 monthly. Linear generalized estimating and log-binomial regression models were used to estimate the effect of KSHV infection on immunologic recovery and response and HIV viral load suppression within 18 months after ART initiation.
RESULTS: Three hundred eighty-five subjects initiating ART from November 2008 to March 2009 were considered to be eligible including 184 (48%) KSHV+. The KSHV+ group was similar to the KSHV- in terms of age, gender, initiating CD4 count, body mass index, tuberculosis, and hemoglobin levels. The KSHV+ group gained a similar number of cells at 6 [difference of 10 cells per cubic millimeter, 95% confidence interval (CI): -11 to 31], 12 (3 cells per cubic millimeter, 95% CI: -19 to 25), and 18 months (24 cells per cubic millimeter, 95% CI: -13 to 61) compared with that gained by the KSHV- group. Adjusted relative risk of failure to suppress viral load to <400 copies per milliliter (1.03; 95% CI: 0.90 to 1.17) were similar for KSHV+ and KSHV- by 6 months on treatment.
CONCLUSIONS: In a population with a high KSHV prevalence, HIV-positive adults coinfected with KSHV achieved similar immunologic and virologic responses to ART early after treatment initiation compared with those with KSHV-.
Authors:
Mhairi Maskew; A Patrick MacPhail; Denise Whitby; Matthias Egger; Matthew P Fox
Related Documents :
196996 - Infectious mononucleosis: recognition and management.
24065326 - Changes in the timing of antiretroviral therapy initiation in hiv-infected patients wit...
24828336 - Microrna-150 is a potential biomarker of hiv/aids disease progression and therapy.
24395716 - Application of serologic assays for diagnosing acute hepatitis e in national surveillan...
11026106 - Minocycline as a cause of drug-induced autoimmune hepatitis. report of four cases and c...
21808406 - Fulminant hepatic failure after repeated exposure to isoflurane.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  63     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-07-01     Completed Date:  2013-09-17     Revised Date:  2014-08-04    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  442-8     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Retroviral Agents / therapeutic use*
Antigens, Nuclear / immunology
CD4 Lymphocyte Count
Coinfection
Female
Glycoproteins / immunology
HIV Infections / complications*,  drug therapy*,  immunology
Herpesviridae Infections / complications*,  immunology
Herpesvirus 8, Human / immunology*
Humans
Linear Models
Male
Middle Aged
Prospective Studies
Viral Load*
Viral Proteins / immunology
Grant Support
ID/Acronym/Agency:
5U01-AI069924-05/AI/NIAID NIH HHS; U01 AI069924/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Retroviral Agents; 0/Antigens, Nuclear; 0/Glycoproteins; 0/K8.1 protein, Human herpesvirus 8; 0/Viral Proteins; 0/latent Orf73 antigen, human herpesvirus 8
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The impact of HIV viral control on the incidence of HIV-associated anal cancer.
Next Document:  Individual, interpersonal, and social-structural correlates of involuntary sex exchange among female...